MediaTek Inc (聯發科), which supplies handset chips to the world’s biggest telecom, China Mobile (中國移動), is expected to take half of China’s smartphone chip market next year, benefiting from the quick uptake of its new octa-core chips used in high-end and mid-range smartphones, Daiwa Capital Markets forecast yesterday.
The gain in market share would help MediaTek widen the gap in its leadership of the Chinese market, the world’s largest. This year, MediaTek is expected to seize a 48 percent share of the Chinese market, Daiwa said.
Meanwhile, major rival Qualcomm Inc is expected to see its market share shrink to 25 percent next year from this year’s 30 percent due to a lack of competitive products in the second half of this year, Daiwa analyst Eric Chen (陳慧明) said in a report.
“On a recent trip to China, we got the impression that MediaTek’s octa-core smartphone IC had been well received. Given this, octa-core ICs could become mainstream [smartphone chips] in China by 2014,” Chen said.
As the octa-core Cortex A7 MT6592 delivers an impressive clock speed of between 1.7 gigahertz and 2 gigahertz and has low power consumption, the chip would help Chinese smartphone makers gain access to the mid-range and high-end large-screen market segment, as well as helping MediaTek boost its global orders, Chen said.
MediaTek said last month that it plans to ramp up production of the new octa-core chip next quarter.
The firm’s new cost-efficient quad-core smartphone processors, code-named the MT6582 and the MT6588, would also help the chipmaker expand its market share in China, Chen said.
The quad-core chips, one for low-end smartphones and another for mid-range models, are expected to launch next quarter, Chen said.
MediaTek is expected to grow its handset shipments by about 44 percent to 300 million units next year, compared with this year’s 208 million units, Chen said.
MediaTek also supplies handset chips to China’s Xiaomi Corp (小米), Lenovo Group (聯想) and ZTE Corp (中興).
This quarter, MediaTek is expected to grow its revenue by 16 percent quarter-on-quarter, a faster pace than the company’s forecast of between 5 percent and 13 percent growth, to between NT$349 billion and NT$376 billion, Chen said.
Net income is expected to increase 24 percent this quarter to NT$8.34 billion, Chen said.
Chen retained his “buy” rating on MediaTek, with a target price of NT$430. That implies a 15 percent upside from the stock’s closing price of NT$374 yesterday.
UNCONVINCING: The US Congress questioned whether the company’s Chinese owners pose a national security risk and how the app might influence young users TikTok chief executive officer Shou Chew (周受資), confronted with an unforgiving, distrustful US Congress, tried to give answers in his testimony on Thursday that avoided offending either the US government or China. However, his evasiveness left Congress unsatisfied, with representatives hungrier than ever to punish TikTok for ties to its parent company ByteDance Ltd (字節跳動), based in Beijing. He did not bring his company any closer to a resolution. Politically, TikTok is in a tougher spot. Its executives had been discussing divesting from ByteDance to resolve US national security concerns, people familiar with the matter told Bloomberg. However, China this week said
Huawei Technologies Co (華為) has replaced more than 13,000 parts in its products that were hit by US trade sanctions, the Chinese tech giant’s founder said, according to a speech transcript from last month posted on Friday by a Chinese university. Ren Zhengfei (任正非) said Huawei had over the past three years replaced the 13,000 components with domestic Chinese substitutes, and had redesigned 4,000 circuit boards for its products, the transcript posted by Shanghai Jiao Tong University said. “As of now, our circuit board [production] has stabilized, because we have a supply of domestically produced components,” Ren said. He did not give details
Sanofi SA’s drug Dupixent succeeded in a late-stage trial for chronic obstructive pulmonary disease (COPD), raising the odds that the blockbuster would be the first biologic medicine cleared to treat the lung disorder. Dupixent, which is already prescribed for asthma and some skin conditions, showed a 30 percent reduction in the rate at which patients’ COPD worsened compared with those who received a placebo during the stage-three Boreas trial, the company said in a statement yesterday. The positive data could herald a new era of cutting-edge treatments for the life-threatening respiratory affliction and provide another major boost in demand for the French
SEMICONDUCTOR EQUIPMENT: The international trade group said the sector would recover from a slump, with spending expected to rise 4.2 percent to US$24.9 billion Taiwan is to retain its position as the top spender on semiconductor front-end equipment and facilities next year, with spending expected to increase 4.2 percent year-on-year to US$24.9 billion, international trade group SEMI said yesterday. The spending forecast matches an expected recovery in global semiconductor equipment and facilities investment next year, it said. International equipment spending is to return to growth next year, SEMI said in a report, forecasting 21 percent growth to US$92 billion. The expansion would manly be driven by robust demand for semiconductors in the automotive and high-performance computing segments, the association said. “This quarter’s SEMI World Fab Forecast update